A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Camostat mesilate (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Adverse reactions
- Acronyms SPIKE-1
Most Recent Events
- 23 May 2022 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2021 Planned End Date changed from 31 Jul 2021 to 31 Dec 2021.
- 12 Oct 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Dec 2021.